MIRA Pharmaceuticals, Inc.

MIRA Healthcare Drug Manufacturers General

In the quarter to June 2026, EPS grew 66.7% and free cash flow fell 50.8%, each against the same quarter a year earlier.

0.63 0.03 −4.55%
Market cap
$27.7M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(710.85%) (589.40%) (508.28%) (510.93%)

+8 more TTM periods

ROA
(684.27%) (577.42%) (456.59%) (477.58%)
ROIC
(12,016.10%) 0.00% 0.00% (32,898.61%)
Return on Tangible Assets
(381.90%) (336.78%) (308.99%) (378.18%)
Average Days of Receivables
— — — —
Free Cash Flow per Share
(0.11) (0.10) (0.20) (0.28)
Free Cash Flow
(4.64) (4.23) (4.66) (5.33)
Other line items

Show all line items

Columns are period end dates